ADMA Biologics (NASDAQ:ADMA) has been assigned a $13.00 price objective by investment analysts at Oppenheimer in a report issued on Wednesday, October 17th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s target price suggests a potential upside of 147.15% from the company’s current price.
A number of other research firms have also weighed in on ADMA. Maxim Group upped their target price on shares of ADMA Biologics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, July 26th. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Raymond James reiterated a “buy” rating and issued a $10.00 price objective (down previously from $11.00) on shares of ADMA Biologics in a research note on Friday, October 12th. Chardan Capital began coverage on shares of ADMA Biologics in a research note on Monday, July 30th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Thursday, July 26th. Eight equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $11.58.
Shares of NASDAQ ADMA traded down $0.48 during trading on Wednesday, hitting $5.26. 177,456 shares of the company traded hands, compared to its average volume of 226,392. ADMA Biologics has a fifty-two week low of $2.10 and a fifty-two week high of $6.96. The firm has a market capitalization of $266.97 million, a P/E ratio of -2.75 and a beta of 2.28. The company has a current ratio of 10.65, a quick ratio of 8.88 and a debt-to-equity ratio of 0.79.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of ADMA Biologics by 2,295.0% during the 2nd quarter. BlackRock Inc. now owns 970,839 shares of the biotechnology company’s stock valued at $4,378,000 after acquiring an additional 930,303 shares during the period. 683 Capital Management LLC boosted its holdings in ADMA Biologics by 9.9% in the 2nd quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after buying an additional 80,000 shares during the period. Stonepine Capital Management LLC bought a new position in ADMA Biologics in the 2nd quarter worth approximately $3,751,000. Millennium Management LLC boosted its holdings in ADMA Biologics by 305.2% in the 1st quarter. Millennium Management LLC now owns 273,621 shares of the biotechnology company’s stock worth $1,259,000 after buying an additional 206,088 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in ADMA Biologics by 54.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock worth $1,422,000 after buying an additional 81,003 shares during the period. 55.07% of the stock is owned by hedge funds and other institutional investors.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.